17th Annual Cardiometabolic Health Congress On-Demand |
- 18.50 CDE
- 18.50 ABIM MOC and AMA PRA Category 1 Credit™
- 18.50 ACPE Pharmacy
- 18.50 AMA PRA Category 1 Credit™
- 18.50 ANCC
- 18.50 Participation
|
Enduring |
|
$0.00 |
A Closer Look: CDKL5 Deficiency Disorder & Rescue Treatment |
- 0.25 ACCME (MD/DO Only)
- 0.25 ACCME (All Other)
- 0.25 ACPE Pharmacy
- 0.25 ANCC
|
Enduring |
|
$0.00 |
A Shifting Paradigm: Translating Research into Treatment Approaches for ALS |
- 1.00 ACCME (MD/DO Only)
- 1.00 ACCME (All Other)
- 1.00 ACPE Pharmacy
- 1.00 ANCC
|
Enduring |
|
$0.00 |
Advanced Education Certification Series: Cannabinoids |
- 11.00 ACCME (MD/DO Only)
- 11.00 AANP
- 11.00 APA
- 11.00 ACCME (All Other)
- 11.00 ACPE Pharmacy
- 11.00 ANCC
|
Enduring |
|
$1,500.00 |
Advanced Education Certification Series: Opioids |
- 15.25 ACCME (MD/DO Only)
- 15.25 AANP
- 15.00 APA
- 15.25 ACCME (All Other)
- 15.25 ACPE Pharmacy
- 15.25 ANCC
|
Enduring |
|
$1,500.00 |
Advanced Education Certification Series: Palliative Care |
- 20.00 ACCME (MD/DO Only)
- 20.00 AANP
- 20.00 APA
- 20.00 ACCME (All Other)
- 20.00 ACPE Pharmacy
- 20.00 ANCC
|
Enduring |
|
$1,500.00 |
An Overview of GLP-1 RAs for CV Risk Reduction in T2DM Patients |
- 1.00 CDE
- 1.00 ABIM MOC and AMA PRA Category 1 Credit™
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
|
Enduring |
|
$0.00 |
BRAINWeek 2022 Digital All Access |
- 22.00 ACCME (MD/DO Only)
- 22.00 AANP
- 22.00 AAFP
- 22.00 APA
- 22.00 ACCME (All Other)
- 22.00 ACPE Pharmacy
- 22.00 ANCC
|
Enduring |
|
$499.00 |
Case Study - Tackling Diabetic Kidney Disease Progression: Challenges, Advances, and Novel Approaches |
- 0.50 CDE
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation
|
Enduring |
|
$0.00 |
Challenging Cases in the Management of Aortic Stenosis in Women |
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 Participation
|
Enduring |
|
$0.00 |
Clinical Brief: Challenges and Advances in Diabetic Kidney Disease |
- 1.00 CDE
- 1.00 ABIM MOC and AMA PRA Category 1 Credit™
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
|
Enduring |
|
$0.00 |
Clinical Brief: IL-13 inhibitors: Advances and Considerations for Managing Moderate-to-Severe Atopic Dermatitis |
- 0.25 AMA PRA Category 1 Credit™
- 0.25 ANCC
- 0.25 Participation
|
Enduring |
|
$0.00 |
Clinical Brief: Prevention and Treatment of Influenza in High-Risk Patients with Cardiometabolic Comorbidities |
- 1.00 CDE
- 1.00 ABIM MOC and AMA PRA Category 1 Credit™
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
|
Enduring |
|
$0.00 |
Clinical Brief: Should Diabetes Management be More Adipose-centric? |
- 0.50 CDE
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation
|
Enduring |
|
$0.00 |
Clinical Brief: The Disproportionate Burden of ATTR-CM In African Americans |
- 0.50 CDE
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation
|
Enduring |
|
$0.00 |